ProGen

ProGen, established in 1998, is a South Korean biopharmaceutical company focused on research and development. The company was founded by Professor Young-chul Sung of POSTECH University in collaboration with Dong-A Pharmaceutical, initially operating as a subsidiary to develop biosimilar production cell lines. This foundation provided ProGen with deep expertise in genetic engineering and cell line development from its inception. Professor Sung, also the founder of Genexine, has played a pivotal role in shaping the company's trajectory, leveraging his academic and entrepreneurial background in life sciences and immunology.

The company's business model centers on its proprietary platform technologies for developing multi-specific fusion protein drugs. ProGen's core strategy involves discovering and advancing new drug candidates and then creating value through co-development partnerships or technology out-licensing to major pharmaceutical companies. A significant milestone was the development of the long-acting fusion protein platform, hyFc®, in collaboration with POSTECH and Genexine. Building on this, ProGen engineered more advanced platforms, pNTIG and NTIG® (Novel Tri-ImmunoGlobulin), which offer improved efficacy and longer-acting profiles for multi-target therapies.

ProGen primarily develops treatments for metabolic diseases, immune disorders, and immuno-oncology. Its flagship project is PG-102, a next-generation treatment for obesity and diabetes that combines GLP-1 and GLP-2 agonists using the NTIG® platform. This dual-agonist approach is designed to not only promote weight loss and control blood sugar but also to improve gut health and potentially preserve muscle mass, addressing key side effects seen with existing GLP-1 treatments. PG-102 is engineered for a longer half-life, allowing for dosing intervals of two to four weeks, which enhances patient convenience. The company has advanced PG-102 into clinical trials and is positioning it as a potential blockbuster drug. Other pipeline candidates include treatments for autoimmune diseases and cancer.

The company generates revenue through technology transfer agreements, licensing deals, and co-development partnerships. A notable example includes the license-out of the GI-301 (an IgE Trap for allergies) technology to GI-Innovation, which was subsequently licensed to Yuhan Corporation and Maruho. ProGen is publicly traded on the KONEX market in South Korea and has established significant partnerships, with Yuhan Corporation becoming its largest shareholder in 2023. This strategic relationship, along with others, is crucial for advancing its pipeline through late-stage clinical trials and global commercialization. Keywords: ProGen, biopharmaceutical, drug development, NTIG platform, multi-specific protein, fusion protein technology, metabolic diseases, obesity treatment, diabetes treatment, PG-102, GLP-1 agonist, GLP-2 agonist, immuno-oncology, autoimmune disease, technology licensing, Young-chul Sung, Yuhan Corporation, KONEX, bioventure, clinical trials, hyFc platform, protein engineering, pharmaceutical R&D, long-acting biologics, South Korean biotech